Chlorpromazine antibody/antigen (BSA/OVA/KLH conjugated hapten)

anti-Chlorpromazine antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)

Target products collectionGo to food safety diagnostics products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-139-11. BSA-Chlorpromazine
2. Anti-Chlorpromazine mouse monoclonal antibody
$2709.00
GMP-SMT-139-21. OVA-Chlorpromazine
2. Anti-Chlorpromazine mouse monoclonal antibody
$2709.00
GMP-SMT-139-31. BSA-Chlorpromazine
2. Anti-Chlorpromazine human monoclonal antibody
$2709.00
GMP-SMT-139-41. OVA-Chlorpromazine
2. Anti-Chlorpromazine human monoclonal antibody
$2709.00
GMP-SMT-139-Ag-1BSA-Chlorpromazine$756.00
GMP-SMT-139-Ag-2OVA-Chlorpromazine$756.00
GMP-SMT-139-Ab-1Anti-Chlorpromazine mouse monoclonal antibody$1953.00
GMP-SMT-139-Ab-2Anti-Chlorpromazine human monoclonal antibody$1953.00

Size: 1mg | 10mg | 100mg



Product Description


BSA-Chlorpromazine

Cat No.GMP-SMT-139-Ag-1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-Chlorpromazine with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-Chlorpromazine had been validated with our anti-Hapten antibody Anti-Chlorpromazine mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


OVA-Chlorpromazine

Cat No.GMP-SMT-139-Ag-2
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates OVA-Chlorpromazine with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-Chlorpromazine had been validated with our anti-Hapten antibody Anti-Chlorpromazine mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-Chlorpromazine mouse monoclonal antibody

Cat No.GMP-SMT-139-Ab-1
Host of AntibodyMouse IgG
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)0.2-0.5
Products descriptionThe anti-Hapten antibody against hapten Chlorpromazine had been validated with our hapten hapten-carrier conjugates BSA-Chlorpromazine via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-Chlorpromazine human monoclonal antibody

Cat No.GMP-SMT-139-Ab-2
Host of AntibodyHuman IgG1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)0.2-0.5
Products descriptionThe anti-Hapten antibody against hapten Chlorpromazine had been validated with our hapten hapten-carrier conjugates BSA-Chlorpromazine via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Biomarker Information


    1. Chlorpromazine's Environmental Significance: Unveiling Its Role

    Scientific Insight:



    Chlorpromazine, a small molecule renowned for its clinical use as an antipsychotic medication, has recently garnered substantial attention within the environmental science community. While originally designed for therapeutic purposes, Chlorpromazine's journey into the environment offers a unique perspective on the complex interactions between pharmaceutical compounds and ecosystems.

    Environmental Role:



    Chlorpromazine's relevance transcends its established role in medicine, finding a new dimension in the environmental domain. Of particular concern is its persistent presence in wastewater effluents and surface waters, stemming from diverse sources such as pharmaceutical manufacturing, healthcare facilities, and domestic use. Consequently, Chlorpromazine is categorized as one of the pharmaceutical residues that may potentially impact aquatic environments. Understanding its environmental implications has become a critical facet of contemporary environmental research.

    Classified as an emerging contaminant, Chlorpromazine beckons the scientific community to delve deeper into its environmental role. This entails a multifaceted investigation, including assessing its fate, behavior, and potential ecological repercussions. Researchers are meticulously examining the persistence of Chlorpromazine in aquatic systems, its potential for bioaccumulation in aquatic organisms, and the ecotoxicological effects it may exert on sensitive ecosystems. By doing so, the complex interplay between Chlorpromazine and the environment is being unraveled, paving the way for a more comprehensive understanding of its environmental footprint.

    Moreover, Chlorpromazine's presence in the environment raises intriguing questions about its transformation and degradation pathways under varying environmental conditions. Researchers seek to elucidate the factors that influence its persistence and reactivity, shedding light on the intricate processes governing the fate of pharmaceutical compounds once they enter aquatic ecosystems.

    2. The Crucial Imperative: Measuring Chlorpromazine for Environmental Insight

    Scientific Explanation:

    The imperative of quantifying Chlorpromazine within environmental matrices is underscored by a multitude of considerations, each of profound significance:

    a. Environmental Surveillance: Chlorpromazine, as an environmental constituent originating from wastewater discharges, necessitates vigilant monitoring in aquatic ecosystems. Quantitative measurements are essential to ascertain the extent of contamination and to track variations in its presence over time. Such surveillance contributes to our ability to gauge the environmental distribution of this pharmaceutical compound.

    b. Emerging Contaminants Focus: Chlorpromazine belongs to the cohort of emerging contaminants, denoting substances whose presence in the environment has raised significant concern. Quantitative assessment is pivotal for tracking not only the prevalence of Chlorpromazine but also its analogs and congeners within environmental compartments. This focus on emerging contaminants underscores the need for precision in monitoring techniques.

    c. Ecotoxicological Assessment: A comprehensive grasp of Chlorpromazine's impact on aquatic biota and ecosystems is paramount. Quantitative analysis furnishes data that allow scientists to gauge its toxicity and potential consequences on aquatic organisms. The examination of dose-response relationships and exposure scenarios aids in deciphering the potential risks associated with its presence in aquatic environments.

    d. Risk Mitigation: Accurate measurement of Chlorpromazine levels empowers risk assessment initiatives, guiding the formulation of mitigation strategies. Proactive measures, stemming from quantitative insights, serve as safeguards against environmental harm. These strategies may include optimizing wastewater treatment processes, implementing regulatory measures, and developing remediation techniques tailored to address Chlorpromazine contamination.

    In summation, measuring Chlorpromazine in environmental contexts is instrumental for environmental surveillance, risk assessment, and ecosystem preservation. Such measurements facilitate a more profound comprehension of pharmaceutical residue impacts and provide a foundational basis for the implementation of strategies aimed at environmental conservation and protection. As we continue to explore the intricate dynamics between pharmaceuticals and the environment, Chlorpromazine serves as a poignant case study highlighting the evolving interplay between medicine and nature.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.